EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic target of leukotriene B4 receptors, BLT1 and BLT2: Insights from basic research

Motonao Nakamura, Takao Shimizu

Biochimie · 2023

DOI: 10.1016/j.biochi.2023.06.014 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimie, 2023. Verfasst von Motonao Nakamura und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience, Graduate School of Life Science, Okayama University of Science, 1-1 Ridai-cho, Kita-ku, Okayama, 700-0005, Japan. Electroni…. Hauptthemen laut MEDLINE: Leukotriene B4, Arthritis, Rheumatoid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leukotriene B4 (LTB4) is a lipid mediator rapidly generated from arachidonic acid in response to various stimuli. This lipid mediator exerts its biological activities by binding to cognate receptors. Two LTB4 receptors have been cloned; BLT1 and BLT2 as a high- and a low-affinity receptors, respectively. In numerous analyses, physiological and pathophysiological importance of LTB4 and cognate receptors in various diseases has been clarified. For example, disruption of the BLT1 gene or treatment with blockers for this receptor reduced various diseases such as rheumatoid arthritis and bronchial asthma in mice, in contrast BLT2 deficiency facilitated several diseases in the small intestine and the skin. These data support the idea that BLT1 blockers and BLT2 agonists could be useful for the cure of these diseases. Thus, various drugs targeting each receptor are being developed by many pharmaceutical companies. In this review, we focus on our current knowledge of the biosynthesis and physiological roles of LTB4 through cognate receptors. We further describe the effects of these receptor deficiencies on several pathophysiological conditions, including the potential of LTB4 receptors as therapeutic targets for the cure of the diseases. Moreover, current information on the structure and post-translational modification of BLT1 and BLT2 is discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukotriene B4Arthritis, RheumatoidMiceAnimalsSkinReceptors, Leukotriene B4

Stichwörter der Autor:innen

BLT1BLT2DiseaseInflammationLeukotriene B(4)PhosphorylationSignalingStructure

Substanzen

Leukotriene B4Receptors, Leukotriene B4

Autor:innen und Institutionen

  • Department of Bioscience, Graduate School of Life Science, Okayama University of Science, 1-1 Ridai-cho, Kita-ku, Okayama, 700-0005, Japan. Electronic address: moto-nakamura@ous.ac.jp.
  • Lipid Signaling, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Institute of Microbial Chemistry, Tokyo, 141-0021, Japan.

Zitieren

APA

Nakamura, M., & Shimizu, T. (2023). Therapeutic target of leukotriene B4 receptors, BLT1 and BLT2: Insights from basic research. Biochimie. https://doi.org/10.1016/j.biochi.2023.06.014

Vancouver

Nakamura M, Shimizu T. Therapeutic target of leukotriene B4 receptors, BLT1 and BLT2: Insights from basic research. Biochimie. 2023. doi:10.1016/j.biochi.2023.06.014

BibTeX
@article{Nakamura2023,
  author = {Nakamura, Motonao and Shimizu, Takao},
  title = {Therapeutic target of leukotriene B4 receptors, BLT1 and BLT2: Insights from basic research},
  journal = {Biochimie},
  year = {2023},
  doi = {10.1016/j.biochi.2023.06.014}
}
Kostenlos starten →